PCI Biotech Holding ASA Cash Flow Conversion Efficiency
PCI Biotech Holding ASA cash flow conversion efficiency. Based on the latest financial reports, PCI Biotech Holding ASA (PCIB) has a cash flow conversion efficiency ratio of -0.501x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-6.26 Million ≈ $-659.15K USD) by net assets (Nkr12.52 Million ≈ $1.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PCI Biotech Holding ASA (2008–2024)
Cash flow conversion efficiency of PCI Biotech Holding ASA from 2008 to 2024. This chart illustrates how PCI Biotech Holding ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PCIB live share price for real-time trading data and today's change.
PCI Biotech Holding ASA Cash Flow Conversion Ratio Explained
PCI Biotech Holding ASA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PCI Biotech Holding ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PCI Biotech Holding ASA ranked by their cash flow conversion efficiency. Also see PCI Biotech Holding ASA (PCIB) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sino-German United AG
F:SGU
|
N/A |
|
Portmeirion Group PLC
LSE:PMP
|
-0.015x |
|
Ming Le Sports AG
F:ML2
|
-0.018x |
|
Sejahtera Bintang Abadi Textile Tbk
JK:SBAT
|
-0.023x |
|
Abingdon Health Plc
LSE:ABDX
|
-0.204x |
|
Virpax Pharmaceuticals Inc
NASDAQ:VRPX
|
3.142x |
|
HARVEST MINERALS LTD
F:7HM
|
N/A |
|
Baltic Bridge S.A.
WAR:WIS
|
N/A |
Annual Cash Flow Conversion Efficiency for PCI Biotech Holding ASA (2008–2024)
The table below shows the annual cash flow conversion efficiency of PCI Biotech Holding ASA from 2008 to 2024. Review PCI Biotech Holding ASA (PCIB) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr23.45 Million ≈ $2.47 Million |
Nkr-13.76 Million ≈ $-1.45 Million |
-0.587x | -53.00% |
| 2023-12-31 | Nkr39.04 Million ≈ $4.11 Million |
Nkr-14.97 Million ≈ $-1.58 Million |
-0.383x | +62.72% |
| 2022-12-31 | Nkr57.40 Million ≈ $6.04 Million |
Nkr-59.04 Million ≈ $-6.21 Million |
-1.029x | -71.35% |
| 2021-12-31 | Nkr113.79 Million ≈ $11.97 Million |
Nkr-68.31 Million ≈ $-7.19 Million |
-0.600x | -46.79% |
| 2020-12-31 | Nkr189.24 Million ≈ $19.91 Million |
Nkr-77.39 Million ≈ $-8.14 Million |
-0.409x | -24.85% |
| 2019-12-31 | Nkr254.83 Million ≈ $26.82 Million |
Nkr-83.47 Million ≈ $-8.78 Million |
-0.328x | -258.30% |
| 2018-12-31 | Nkr339.95 Million ≈ $35.77 Million |
Nkr-31.08 Million ≈ $-3.27 Million |
-0.091x | +87.51% |
| 2017-12-31 | Nkr41.84 Million ≈ $4.40 Million |
Nkr-30.62 Million ≈ $-3.22 Million |
-0.732x | +73.17% |
| 2016-12-31 | Nkr13.09 Million ≈ $1.38 Million |
Nkr-35.69 Million ≈ $-3.76 Million |
-2.728x | -267.80% |
| 2015-12-31 | Nkr44.28 Million ≈ $4.66 Million |
Nkr-32.84 Million ≈ $-3.46 Million |
-0.742x | +78.66% |
| 2014-12-31 | Nkr9.11 Million ≈ $959.06K |
Nkr-31.67 Million ≈ $-3.33 Million |
-3.475x | -427.45% |
| 2013-12-31 | Nkr43.40 Million ≈ $4.57 Million |
Nkr-28.59 Million ≈ $-3.01 Million |
-0.659x | -88.59% |
| 2012-12-31 | Nkr69.71 Million ≈ $7.34 Million |
Nkr-24.35 Million ≈ $-2.56 Million |
-0.349x | -69.72% |
| 2011-12-31 | Nkr92.53 Million ≈ $9.74 Million |
Nkr-19.05 Million ≈ $-2.00 Million |
-0.206x | -104.92% |
| 2010-12-31 | Nkr105.42 Million ≈ $11.09 Million |
Nkr-10.59 Million ≈ $-1.11 Million |
-0.100x | +79.07% |
| 2009-12-31 | Nkr35.08 Million ≈ $3.69 Million |
Nkr-16.84 Million ≈ $-1.77 Million |
-0.480x | -151.50% |
| 2008-12-31 | Nkr49.30 Million ≈ $5.19 Million |
Nkr-9.41 Million ≈ $-990.10K |
-0.191x | -- |
About PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more